About BioLipox
BioLipox is a Healthcare company based in Solna (Sweden) founded in 2000, and was acquired by Orexo in October 2007. It operates as an arachidonic acid-based drugs are developed for respiratory and inflammatory diseases. BioLipox has raised $68.57 million across 4 funding rounds from investors including Orexo, Scandinavian Life Science Venture and Auriga Partners. BioLipox has completed 1 acquisition, including Inflazyme. Its focus areas include Life Sciences, Pulmonology, Drugs and Diversified. Its competitors include aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria and 3 more; 7 of its 8 listed competitors have raised funding.
Company details
Biolipox researches and develops treatments for respiratory and inflammatory diseases. The Company provides arachidonic acid research and drugs for the treatment of asthma, chronic obstructive pulmonary diseases, rhinitis, and arthritis. In 2007, Biolipox AB was acquired by Orexo. It focuses on arachidonic acid based drugs primarily for the treatment of asthma, COPD, rhinitis, pain, and arthritis. The companys product portfolio includes (1) NLA Nasal Spray for the treatment of allergic and non-allergic rhinitis (2) Selective PGE2 synthase inhibitor, for the treatment of pain, osteoarthritis, and rheumatoid arthritis (3) Eoxin inhibitor for asthma, COPD, and other inflammatory diseases. It also develops dual effect respiratory drug, a preclinical product for the treatment of asthma and COPD
- Headquarters Solna, Sweden
- Stage Acquired
- SectorsHealthcare
- Website biolipox.com
- Social Facebook
- Acquired by Orexo (Oct 2007)
Funding Insights of BioLipox
BioLipox has successfully raised a total of $68.57M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $41 million completed in January 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $68.57M
- Total Rounds 4
- Last Round Series C — $41M
- First Round $554,098
(Jun 2000)
- Investors Count 4
All 4 funding rounds of BioLipox with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2005 | $41M | Series C | – | Scandinavian Life Science Venture | – |
| Jan 2003 | $22.52M | Series B | – | – | |
| Mar 2001 | $4.5M | Series A | – | – | |
| Jun 2000 | $554,098 | Seed | – | – |
5 investors in total: 5 institutional.
Investors in BioLipox
BioLipox has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Orexo, Scandinavian Life Science Venture and Auriga Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are made by Auriga Partners in France. | 1998 | auriga.vc | Paris, France | |
- | – | healthcap.eu | - | |
Life Sciences sector focused early stage VC firm investing primarily in Europe | – | sofinnova.fr | Paris, France | |
- | – | slsinvest.com | - | |
Therapeutics for mental illness and substance use disorders are developed. | 1995 | orexo.com | Uppsala, Sweden |
Investor details for BioLipox
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioLipox
BioLipox has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Inflazyme.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Develops LSAIDs against inflammatory diseases and PDE inhibitors against CNS diseases | inflazyme.com | Richmond, Canada | 1992 | Sep 2007 | •••• |
Complete acquisition details for BioLipox
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of BioLipox
Competitors of BioLipox
BioLipox has 8 listed competitors in our database, 7 of them funded. They include aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atyrpharma.com | 2005 | San Diego, United States | $171.52M | 65 | Protein biologics are developed for treating rare diseases. | |
| recodetx.com | 2015 | Menlo Park, United States | $371M | – | Precision medicines for lung-related diseases are developed. | |
| gen1e.com | 2018 | Palo Alto, United States | $17.15M | – | Developer of therapeutics for the treatment of inflammatory and rare diseases | |
| enterprisetherapeutics.com | 2014 | Brighton, United Kingdom | $86.19M | 9 | Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis | |
| ikaria.com | 2005 | Hampton, United States | $434.92M | 429 | Therapies for respiratory-related cardiopulmonary disorders are developed. | |
| pulmatrix.com | 2003 | Lexington, United States | $67.11M | 28 | Developer of therapeutics for the treatment of respiratory diseases | |
| veronapharma.com | 2005 | London, United Kingdom | $56.02M | 27 | Respiratory disease drugs for asthma and COPD are developed. | |
| intermune.com | 1998 | Brisbane, United States | – | 359 | Therapies in pulmonology and orphan fibrotic diseases. |
Detailed competitors of BioLipox
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pulmonology
10 companies that operate in the same segment as BioLipox (Pulmonology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 | |
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | – | 91 | |
Cancer detection diagnostics assays are developed and offered. | 2005 | Boulder, Colorado, United States | USD 200.16 M | USD 88.5 M | 273 | |
Therapeutic devices for nasal breathing improvement are developed. | 2011 | Sunnyvale, California, United States | USD 176.4 M | – | 66 | |
Non-invasive breath-based diagnostics for cancer and infectious diseases are developed. | 2004 | Cambridge, Cambridgeshire, United Kingdom | USD 166.55 M | – | 202 | |
Protein biologics are developed for treating rare diseases. | 2005 | San Diego, California, United States | USD 171.52 M | USD 190 K | 59 | |
Therapeutics for rare respiratory diseases are developed by Savara Pharma. | 2008 | Austin, Texas, United States | USD 67.82 M | – | 59 | |
Developer of smart devices for treating pulmonary diseases | 1998 | Redwood City, California, United States | USD 280.91 M | USD 90.5 M | 291 | |
A norovirus vaccine is developed for infection prevention. | 2021 | Boston, Massachusetts, United States | USD 135 M | – | 14 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biolipox
Complete news archive for BioLipox
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioLipox
BioLipox was founded in 2000.
BioLipox is headquartered in Solna, Sweden.
BioLipox is a funded company, having raised a total of $68.57M across 4 funding rounds to date. The company's 1st funding round was a Seed of $554.1K, raised on Jun 2000.
Biolipox researches and develops treatments for respiratory and inflammatory diseases. The Company provides arachidonic acid research and drugs for the treatment of asthma, chronic obstructive pulmonary diseases, rhinitis, and arthritis. In 2007, Biolipox AB was acquired by Orexo. It focuses on arachidonic acid based drugs primarily for the treatment of asthma, COPD, rhinitis, pain, and arthritis. The companys product portfolio includes (1) NLA Nasal Spray for the treatment of allergic and non-allergic rhinitis (2) Selective PGE2 synthase inhibitor, for the treatment of pain, osteoarthritis, and rheumatoid arthritis (3) Eoxin inhibitor for asthma, COPD, and other inflammatory diseases. It also develops dual effect respiratory drug, a preclinical product for the treatment of asthma and COPD.
BioLipox's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
BioLipox has made 1 acquisition, including Inflazyme.
BioLipox has 5 investors. Key investors include Orexo, Scandinavian Life Science Venture, Auriga Partners, Healthcap, and Sofinnova.
Yes. BioLipox was acquired by Orexo in October 2007.